Maijie operates a comprehensive translational-medicine platform offering nucleic acid, protein, pathology and cell-biology services and develops companion-diagnostic products for precision oncology and drug development. The company traces its origins to an Asia‑Pacific translational medicine center joint‑ventured with Germany's QIAGEN and was founded in 2013 in Suzhou. Maijie has established and validated over 200 assay methodologies covering more than 100 biomarkers and targets, serves over 200 domestic and international clients, and has strategic collaborations with more than ten innovative drug and biotech companies. Several diagnostic products are already on the market; multiple products are in clinical trials or under regulatory review, and more than a dozen nucleic‑acid and protein products are in the R&D pipeline across targeted, immune and cell therapies. The company plans to use new capital to expand its full translational‑medicine platform, accelerate companion‑diagnostic R&D and product registration, build sales networks, expand overseas R&D and service capabilities, and strengthen commercial promotion. These efforts are intended to better support global drug developers and improve precision treatment for cancer patients.

Total raised

$51M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2020